Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.

After receiving an intraocular injection of the gene for a light-sensitive protein, a 58-year-old man diagnosed with the neurodegenerative eye disease retinitis pigmentosa was able to locate objects on a table using engineered goggles.

Four dozen children with severe combined immunodeficiency (SCID) who received a corrective gene carried by a virus have working immune systems two to three years later, according to three independent clinical trials.

Immunization had up to 77 percent efficacy in a Phase 2 clinical study of 450 children in Burkina Faso.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.

Geeta Swamy of Duke University School of Medicine speaks with The Scientist about starting what she considers a long-overdue clinical study of COVID-19 vaccines in pregnant women.